Adalvo is actively advancing Tafamidis 61mg Soft Gel Capsules to meet the increasing demand in the Transthyretin-Related Amyloidosis (ATTR) market, with a DCP submission planned for July 2025.
As the only approved oral treatment for ATTR cardiomyopathy, Tafamidis plays a critical role in reducing cardiovascular mortality. With a strong IP strategy and experimental support on this difficult-to-develop product, Adalvo is on track for a day-1 launch.
Total 2024 global sales for Tafamidis INN reached $6.2 billion, with a 3-year CAGR of 34%, according to IQVIA.
Manufactured in a state-of-the-art facility, Tafamidis benefits from a clearly defined pathway and competitive cost of goods, making it a unique yet high-value opportunity.
Adalvo remains focused on expanding access to Tafamidis as part of its rare disease portfolio.
Contact our team to explore commercial opportunities.